Rare Diseases and Orphan Drug Policies
Each rare disease affects few people, but together rare diseases affect hundreds of millions worldwide. Patients often face long delays in diagnosis, few treatments and high costs. Orphan drug policies aim to encourage new treatments.
The Rare Diseases and Orphan Drug Policies session at GCPE 2027 covers rare disease research and policy. It connects closely with precision public health and genomic epidemiology, as most rare diseases are genetic.
Around 300 million people worldwide live with a rare disease. Many wait years for a correct diagnosis. Treatments exist for only a small share of rare conditions. Policies aim to encourage research and improve access.
Key Topics in Rare Diseases and Orphan Drug Policies
• Rare disease epidemiology and registries
• Diagnostic delays
• Newborn screening for rare conditions
• Orphan drug incentives
• Access and pricing of rare disease treatments
• Health technology assessment for orphan drugs
• Patient organisations and advocacy
• Care coordination for rare diseases
• International collaboration
• Ethical issues in rare disease research
Recent Advances in Rare Diseases and Orphan Drug Policies
Genomic testing is shortening the diagnostic journey for many families. New gene therapies offer hope but come at very high prices, a challenge discussed in health economics and healthcare management.
Policy approaches to access are explored in public health policy, ethics and governance, and international partnerships link with global health and international healthcare systems.
Genomic testing is speeding up diagnosis for many families. Newborn screening programmes are expanding. New gene therapies are offering hope but at high cost. International networks are pooling expertise and data.
Who Should Attend the Rare Diseases and Orphan Drug Policies Session
• Rare disease clinicians and researchers
• Policy makers and health technology assessors
• Patient organisations
• Geneticists
• PhD students and early-career researchers
• Pharmaceutical professionals
Why Present Your Research in Rare Diseases and Orphan Drug Policies
Presenting at GCPE 2027 lets you share rare disease research with an international audience. You can connect with colleagues in maternal, child and adolescent health caring for children with rare conditions. Rare disease work benefits from global collaboration. Presenting here helps your work reach patients and policy makers.
Frequently Asked Questions
Can patient organisations present?
Yes. Patient organisations are welcome to submit.
Does this session cover drug pricing?
Yes. Access and pricing are key topics.
Where is GCPE 2027 held?
GCPE 2027 is held at Delta Hotels Heathrow Windsor, London, UK, from 17 to 19 May 2027, with online participation.